Recent meta-analyses (4–6) of a newer antihyperglycemic drug class [i.e., sodium-glucose cotransporter 2 inhibitors (SGLT2i): empagliflozin (7), canagliflozin (8), and dapagliflozin (9)] have demonstrated benefits in lowering fatal and non-fatal CVD, all-cause mortality, hospitalization with heart failure (HF), and declining kidney function in patients with T2DM (4), irrespective of glycemic control and baseline metformin and/or statin use (10). Here, SLC5A2 is linked to type 2 diabetes mellitus.